Biotech Values

[DewDiligence]

GNFT.PA’s phase-3 NASH trial has slower-than-expected enrollment:

https://t.co/mTwQYz3Ngq

While enrollment of patients with F1 fibrosis stage is in advance of expectations, patients with F2 and F3 fibrosis stages follow a more moderate enrollment curve compared to the initial projections. Enrolment of the first ~1000 patients to participate in the first phase of the trial is therefore expected to be completed in Q1 2018.

This change of 4 to 6 months from the current timeline is partly due to the increasing number of clinical trials now being launched in NASH…

As noted in 2015, I think GNFT embarked on a phase-3 trial prematurely (#msg-118573252).

h/t @bio_clouseau.